Magdalena Meissner
Myfyriwr ymchwil, Cancer & Genetics, Yr Ysgol Meddygaeth
Mae'r cynnwys hwn ar gael yn Saesneg yn unig.
Trosolwg
Ymchil
Traethawd ymchwil
Investigation of Biomarker determinants of treatment efficacy of fulvestrant and the AKT inhibitor AZD5363 in Oestrogen receptor positive breast cancer
Cyhoeddiadau
2024
- Vasileva-Slaveva, M., Morales-Espinosa, D., Puccini, A., Meissner, M., Milic, M., Lamberti, G. and Altena, R. 2024. Tackling hurdles in front of young clinical investigators in oncology – Results from an international survey. European Journal of Surgical Oncology 50(6), article number: 108031. (10.1016/j.ejso.2024.108031)
2023
- Meissner, M., Napolitano, A., Thway, K., Huang, P. and Jones, R. L. 2023. Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?. Expert Opinion on Pharmacotherapy 24(12), pp. 1395-1401. (10.1080/14656566.2023.2224500)
2022
- Howell, S. J. et al. 2022. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology 23(7), pp. 851-864. (10.1016/s1470-2045(22)00284-4)
2021
- Meissner, M. 2021. Investigation of biomarker determinants of treatment response of fulvestrant and capivasertib in oestrogen receptor positive breast cancer. PhD Thesis, Cardiff University.
2016
- Meissner, M. and Addeo, A. 2016. Intrathecal methotrexate and craniospinal radiotherapy can be an effective treatment of carcinomatous meningitis in patients with breast cancer: case reports. Case Reports in Oncology 9(3), pp. 586-592. (10.1159/000449448)